



Guidance on regulations  
for the  
**Transport of Infectious  
Substances 2017–2018**

Applicable as from 1 January 2017



© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Guidance on regulations for the transport of infectious substances 2017-2018. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent

approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Acknowledgement

The extracts from the Recommendations on the *Transport of Dangerous Goods, Model Regulations*, 19th revised edition, New York and Geneva, United Nations, 2015 are reproduced by kind permission of the United Nations.

### Note to the reader:

This document replaces the *WHO Guidance on regulations for the transport of infectious substances 2015-2016*.

For the reader's ease, updated text is highlighted as follows:

- ❖ modified text



# Contents

## Contents

<b>Acknowledgement .....</b>	<b>4</b>
<b>Contents .....</b>	<b>1</b>
International regulations .....	4
National regulations .....	4
<b>Definitions .....</b>	<b>5</b>
Infectious substances .....	5
Cultures .....	5
Patient specimens .....	5
Biological products .....	5
Medical or clinical wastes .....	5
<b>Classification.....</b>	<b>6</b>
Category A.....	6
Category B .....	6
Exemptions .....	6
Biological products .....	8
Genetically modified microorganisms and organisms .....	8
Medical or clinical wastes.....	8
Infected animals.....	9
<b>General preparation of shipments for transport.....</b>	<b>9</b>
Basic triple packaging system.....	9
<b>Packaging, labelling and documentation requirements for infectious substances in Category A .....</b>	<b>10</b>
Packaging.....	10
Marking.....	12
Labelling.....	12
Documentation.....	14
<b>Packaging, labelling and documentation requirements for infectious substances in Category B .....</b>	<b>16</b>
Packaging.....	16
Marking.....	17
Documentation.....	17
<b>Overpacks .....</b>	<b>18</b>
<b>Reusing packaging materials.....</b>	<b>18</b>
<b>Shipping empty packagings .....</b>	<b>18</b>
<b>Refrigerants .....</b>	<b>18</b>
<b>Training .....</b>	<b>19</b>
<b>Recommendations for countries that have not adopted the United Nations system .....</b>	<b>19</b>
<b>Transport planning.....</b>	<b>20</b>
The shipper (sender, consignor).....	20
The carrier.....	20
The receiver (consignee).....	21
<b>Requirements for air mail .....</b>	<b>21</b>
<b>Spill clean-up procedure .....</b>	<b>21</b>
<b>Incident reporting.....</b>	<b>22</b>
<b>Annex 1 Additional information on the United Nations System for the Transport of Dangerous Goods.....</b>	<b>23</b>
<b>Annex 2 Examples of infectious substances included in Category A.....</b>	<b>24</b>

<b>Annex 3 Packing Instruction P620 .....</b>	<b>26</b>
<b>Annex 4 Packing Instruction P650 .....</b>	<b>28</b>
<b>Annex 5 List of dangerous goods related to the transport of infectious substances .....</b>	<b>31</b>
<b>Annex 6 Special Provisions applicable to certain substances .....</b>	<b>32</b>
<b>Annex 7 Flowchart for the classification of infectious substances and patient specimens .....</b>	<b>35</b>

## Introduction

Infectious substances are transported for a variety of different reasons, within countries and across international borders. It is incumbent upon shippers to ensure packaging and shipping conditions meet regulatory requirements to preserve the integrity of materials, and facilitate their timely arrival at destination.

Postal, airline and other transport industry personnel may have concerns about the possibility of becoming infected as the result of exposure to infectious microorganisms that may escape from broken, leaking or improperly packaged material. The packaging of infectious substances for transport must therefore be designed to minimize the potential for damage during transport. In addition, the packaging must ensure the integrity of the materials and so, in turn, timely and accurate processing of specimens.

The following guidelines provide information for classifying infectious substances for transportation and ensuring their safe packaging. They stress the importance of developing a working relationship between those involved – the sender, the carrier and the receiver – in order to provide for safe and expeditious transport of these materials.

- ❖ These guidelines provide practical guidance to facilitate compliance with applicable international regulations for the transport of infectious substances and patient specimens by all modes of transport, both nationally and internationally, and include the changes that apply from 1 January 2017. They replace the guidelines issued by the World Health Organization (WHO) in 2015 (document WHO/CDS/IHR/2015.2). This publication, however, does not replace national and international transport regulations.

Today, thousands of samples of infectious substances need to be shipped and are shipped daily around the world. Human and animal specimens are collected and shipped for a variety of reasons, including disease investigations, clinical trials, surveillance studies, antidoping testing, routine analyses, etc. Regular and occasional shippers consign infectious substances for transport on a daily basis. These include the pharmaceutical industry, health care facilities, diagnostic and research laboratories, medical practitioners, and individual patients.

In the interest of global public health, human and animal specimens need to be transported safely, timely, efficiently and legally from the place where they are collected to the place where they will be analyzed. Regardless of the presumed infection status of the patient, specimens of human and animal origin should be packaged and transported in such a way as to protect those engaged in transportation from the risk of infection. Risks of infection of personnel involved in transport may not be fully eliminated. However, they can undoubtedly be kept to a minimum. In addition, damage to packaging also means that samples dispatched for urgent tasks like analyses are unlikely to arrive to destination on time.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26628](https://www.yunbaogao.cn/report/index/report?reportId=5_26628)

